[Mechanism of isinglass in prevention and treatment of chronic atrophic gastritis in rats].
OBJECTIVE
To investigate the mechanism of isinglass in the prevention and treatment of chronic atrophic gastritis (CAG) in rats.


METHODS
Animal models of SD rats with CAG were made in accordance with the previous experience of combined administration of 60% ethanol, 20 mmol x L(-1) sodium deoxycholate and 0.1% ammonia water. In prevention groups, sucralfate and isinglass were used as preventive therapy while CAG rat model was being made. In the reverse groups, sucralfate and isinglass were used to treat rats after establishment of CAG rat model. Finally all the rats were executed. Then the length of the proliferation zone of the gastric mucosa and serum epidermal growth factors (EGF) and growth hormones (GH)level were studied.


RESULTS
In isinglass prevention groups and high dose isinglass reverse group, the length of the proliferation zone of the gastric mucosa was very close to that in normal control group (P > 0.05), much better than model control group (P < 0.01). In low dose isinglass reverse group, it was lower than that in normal control group (P < 0.01), but much better than model control group (P < 0.01). In both prevention and reverse groups, serum EGF level was higher than that in normal (P < 0.01) and model control group (P < 0.05). Serum GH level was the same in every group (P > 0.05).


CONCLUSIONS
The mechanism of isinglass in the prevention and treatment of CAG rats lies in revitalizing and proliferating gastric mucosal cells by stimulating endogenous EGF secretion.
Si
Jian-min
JM
Gastroenterologic Laboratory of Clinical Institute, Sir Run Run Shaw Hospital Affiliated to Medical School of Zhejiang University, Hangzhou 310016, China. Sijm@163.net
Xu
Miao
M
Wang
Liang-jing
LJ
Wang
Hai-yun
HY
Wu
Jia-guo
JG
Cao
Qian
Q
D000818:Animals; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004815:Epidermal Growth Factor / Q000097:blood; D005260:Female; D005757:Gastritis, Atrophic / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control; D005780:Gelatin / Q000008:administration & dosage / Q000627:therapeutic use*; D013006:Growth Hormone / Q000097:blood; D008419:Materia Medica / Q000008:administration & dosage / Q000627:therapeutic use*; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley
D008419:Materia Medica; D018809:Proliferating Cell Nuclear Antigen; D004815:Epidermal Growth Factor; D005780:Gelatin; D013006:Growth Hormone; C005123:isinglass